quote from 2017 final results23 May 2018 11:58
In the last 12 months commercial deals have focused on joint development, cost sharing, or option agreements with partners contributing funding in return for certain future rights. The next 12 months will see the Company transition from a technology company to a product company building revenues streams from a diverse range of products. This process started in August 2016 with the launch of GoFigure� products and continues with the launch of our LPLDL� cholesterol reducing strain in May 2017. We hope the launch of first generation SweetBiotix� later this year will complete the launch of innovative microbiome products across all our technology platforms.